CD37 and diffuse large B-cell lymphoma: The selection of the OCI-LY3 cell line was based on various characteristics: (i) the origin of the cell was not from a young patient but from a middle-aged man with a stage IV DLBCL that reflects more our population (64% elderly male; 86% stage III-IV); (ii) the cell line is CD20+, CD19+, CD37+ and CD80+ that opens the possibility to future in vitro combination of metronomic chemotherapy with target therapies such as rituximab, tafasitamab or antiCD37 antibodies; (iii) the cell line has been described to harbor 3–4 copies of cMYC and the rearrangements of BCL-2 and BCL-6 [23].